Novel Risk Genes Identified for Bipolar Disorder
By LabMedica International staff writers Posted on 10 Feb 2017 |
Image: The Infinium OmniExpress-24 Kit - This 24-sample BeadChip array offers exceptional throughput of thousands of samples per week, enabling powerful human genome-wide association studies (GWAS) (Photo courtesy of Illumina).
Bipolar disorder (BD) is a common psychiatric disorder characterized by mood swings between positive manic/hypomanic and negative/depressive states, with a lifetime prevalence of more than 1%.
Although epidemiological studies indicate that genetic components contribute to BD development, several genome-wide association studies (GWAS) identified limited number of susceptibility (risk) genes for BD, most of which are yet unidentified.
A collaboration of scientists under the auspices of those at Fujita Health University performed GWAS on 1,612 BD subjects, with 1,545 BD cases remaining after genotype quality control (QC) (Phase I); and the Phase II GWAS initially included 1,604 BD subjects, with 1,419 BD cases remaining after QC. For the Phase I study, the controls comprised 7,408 subjects who were genotyped in a previous GWAS as case subjects for five non-psychiatric disorders (cerebral aneurysm, esophageal cancer, endometrial cancer, chronic obstructive pulmonary disease and glaucoma) or as healthy volunteers. The controls for the Phase II study included 54,479 subjects who had also been genotyped as case subjects for 14 non-psychiatric disorders.
Genotyping was performed using the Illumina HumanOmniExpress v1 chip. The investigators identified a novel risk gene fatty acid desaturase genes (FADS1 and FADS2) for bipolar disorder via GWAS performed using samples collected in Japan of 2,964 cases and 61,887 comparison subjects. The function of this gene is well established: metabolism of lipids, including blood lipids (e.g., cholesterol and triglyceride) and omega3/6 polyunsaturated fatty acids (PUFA). The team then then conducted a meta-analysis between their samples and results from the publicly available BD GWAS database. They identified an additional novel gene for BD, nuclear family I/X (NFIX), and supported three previously implicated genes. The BD ‘risk’ effect is shared between Japanese and European populations. The study was published on January 24, 2017, in the journal Molecular Psychiatry.
Although epidemiological studies indicate that genetic components contribute to BD development, several genome-wide association studies (GWAS) identified limited number of susceptibility (risk) genes for BD, most of which are yet unidentified.
A collaboration of scientists under the auspices of those at Fujita Health University performed GWAS on 1,612 BD subjects, with 1,545 BD cases remaining after genotype quality control (QC) (Phase I); and the Phase II GWAS initially included 1,604 BD subjects, with 1,419 BD cases remaining after QC. For the Phase I study, the controls comprised 7,408 subjects who were genotyped in a previous GWAS as case subjects for five non-psychiatric disorders (cerebral aneurysm, esophageal cancer, endometrial cancer, chronic obstructive pulmonary disease and glaucoma) or as healthy volunteers. The controls for the Phase II study included 54,479 subjects who had also been genotyped as case subjects for 14 non-psychiatric disorders.
Genotyping was performed using the Illumina HumanOmniExpress v1 chip. The investigators identified a novel risk gene fatty acid desaturase genes (FADS1 and FADS2) for bipolar disorder via GWAS performed using samples collected in Japan of 2,964 cases and 61,887 comparison subjects. The function of this gene is well established: metabolism of lipids, including blood lipids (e.g., cholesterol and triglyceride) and omega3/6 polyunsaturated fatty acids (PUFA). The team then then conducted a meta-analysis between their samples and results from the publicly available BD GWAS database. They identified an additional novel gene for BD, nuclear family I/X (NFIX), and supported three previously implicated genes. The BD ‘risk’ effect is shared between Japanese and European populations. The study was published on January 24, 2017, in the journal Molecular Psychiatry.
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer